CTX001 shows durable sickle cell benefits

Casgevy is a gene-edited blood stem cell therapy. It used to be called CTX001 in trials. And the reason people still talk about it with that old name is simple — this was the first CRISPR program that had to prove the hard part wasn’t just getting a dramatic early result, but making that result last. The newer follow-up says it is lasting, in both sickle cell disease and transfusion-dependent beta thalassemia. (astctjournal.org) ### What is this therapy actually doing? The therapy takes a patient’s own blood-forming stem cells, edits them outside the body with CRISPR/Cas9, and then puts them back after chemotherapy conditioning. The edit does not directly fix the sickle mutation. Instead, it turns fetal hemoglobin back on by editing the BCL11A erythroid enhancer. Basically, it makes red blood cells produce a form of hemoglobin that resists sickling and can compensate for faulty adult hemoglobin. (astctjournal.org) ### Why was durability the real question? Early responses in these diseases can look amazing. But the whole bet depends on edited stem cells engrafting for the long haul. If those cells fade, the disease comes back. That is why the long-term rollover study matters so much — CLIMB-131 is still tracking people for years after the original treatment, with completion stretching out to 2039. (clinicaltria([astctjournal.org)he newer follow-up is not about a brand-new approval. That happened earlier — the U.S. cleared Casgevy in December 2023 for eligible patients 12 and older with sickle cell disease and later for transfusion-dependent beta thalassemia. What changed is the amount of time on the clock. By late 2025, Vertex and investigators were presenting follow-up beyond 5 years in sickle cell disease and beyond 6 years in beta thalassemia, with benefits still holding up. (investors.vrtx.com) ### What are the sickle cell results people care about? For sickle cell disease, the headline outcome is freedom from vaso-occlusive crises — the painful, dangerous events that drive hospitalizations and organ damage. The long-term follow-up presented in 2025 described durable benefit after one infusion, with patients from CLIMB SCD-121 and the long-(investors.vrtx.com) crises is what changes daily life. (ashpublications.org) ### What about beta thalassemia? The beta-thalassemia story is the mirror image. Instead of tracking pain crises, researchers track whether patients still need regular transfusions. Long-term follow-up has shown sustained transfusion independence in many treated patients, again years after infusion. That is not just a lab win — it means escaping the cycle of chronic transfusions and iron overload management. (astctjournal.org) ### Does this show up in real life, not just charts? Yes — and that is one reason the story has held attention. Separate quality-of-life analyses published in 2025 showed patients reporting meaningful gains in physical, emotional, social, and functional well-being after exa-cel, with improvements appearing by 6 months and persisting through follow-up. Median follow-up in those reports was 33.6 months in sickle cell disease and 38.4 months in beta thalassemia. (hematology.org) ### So is the problem solved? Not really. The therapy is still intense. Patients need stem-cell collection, myeloablative chemotherapy, hospitalization, and specialized centers. Access is the catch — not just price, but logistics and who is healthy enough to go through transplant-style treatment. Vertex is also pushing into younger children, with first pivotal data in ages 5 to 11 presented in December 2025 and regulatory filings planned for 2026. (investors.vrtx.com) ### Bottom line? The important update is not that CRISPR can produce a dramatic one-time response. We knew that. The important update is that CTX001 — now Casgevy — is starting to look durable on the timescale that actually matters for lifelong blood diseases. That does not make it easy or broadly accessible yet. But it does make the core scientific promise look a lot more real. (astctjournal.org)